Exhibit 99.1

Tuesday April 9, 10:09 am Eastern Time

Press Release

SOURCE: Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals to Present At Suntrust Robinson Humphrey 31st Annual
Institutional Conference

RALEIGH, N.C.--(BUSINESS WIRE)--April 9, 2002--Salix Pharmaceuticals, Ltd.
(Nasdaq:SLXP - news) today announced that the Company will present at the
        ----   ----
SunTrust Robinson Humphrey Institutional Conference in Atlanta, Georgia on
Tuesday, April 16, 2002 at 1:25 p.m. EDT.

Interested parties can access a live audio webcast of the presentation at or
http://www.suntrustrh.com or http://www.salixpharm.com. A replay of the
-------------------------    -------------------------
presentation will be archived and available through April 22.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops
and markets prescription pharmaceutical products for the treatment of
gastrointestinal diseases. Salix's strategy is to in-license late-stage or
marketed proprietary therapeutic drugs; complete the required development and
regulatory submission of these products; and market them through the Company's
60-member gastroenterology specialty sales force. Salix's lead product is
COLAZAL(R), an anti-inflammatory drug approved for the treatment of mildly to
moderately active ulcerative colitis. The Company launched the product in the
U.S. through its specialty sales force in January 2001. COLAZAL was well
tolerated in clinical studies. In clinical trials, patients reported the
following adverse events most frequently: headache (8%); abdominal pain (6%);
diarrhea (5%); nausea (5%); vomiting (4%); respiratory infection (4%); and
arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to
placebo. Salix's next product candidate is LUMENAX(TM) (rifaximin), currently in
development for the potential treatment of infections of the lower
gastrointestinal tract. The Company submitted an NDA for rifaximin for the
treatment of travelers' diarrhea to the FDA on December 26, 2001. Salix trades
on the Nasdaq National Market under the ticker symbol "SLXP." For more
information please contact the Company at 919-862-1000 or visit our web site at
www.salixpharm.com.
------------------

Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include risks of regulatory review and
clinical trials, the need to acquire additional products and management of rapid
growth. The reader is referred to the documents that the Company files from time
to time with the Securities and Exchange Commission.



Contact:

     Salix Pharmaceuticals, Ltd.
     Adam C. Derbyshire, Vice President and Chief Financial
     Officer, 919/862-1000
      or
     Mike Freeman
     Director, Investor Relations and Corporate
     Communications, 919-862-1000